Advanced gout – case study
Keywords:
gout / gouty arthritis, tophi, treatment reducing levels of uric acidAbstract
Gout is a disease caused by a deposit of monosodium urate crystals in the tissue. Joints are frequently affected, which is usually manifested by attacks of severe pain, swelling of the affected joint. The deposit of monosodium urate crystals is caused by the increased level of uric acid in the blood (hyperuricemia) above 6.5 mg / dl, which is the result of its excessive production or decreased excretion from the body. Gout occurs in 1-2% of the population, mostly middle-aged and elderly men (7% of men over 65 suffer from this condition). Women are diagnosed with gout less frequently, and the disease develops almost exclusively after menopause[1]. The incidence of gout clearly increases together with population ageing, lifestyle changes and eating habits. Excessive production of uric acid may be also caused by taking diuretics (especially thiazides) and acetylsalicylic acid in lower doses as well as high consumption of meat, seafood and alcohol (especially beer). This paper presents a case of 55-year-old man suffering from gout in chronic (advanced) stage with significant damage to the locomotor system. The first symptoms suggested a diagnosis of early stages of rheumatoid arthritis. Only after some time gout symptoms became more evident. The patient was treated with uric acid production blockers since the onset of the disease occurred. Even though he also used a low-purine diet and rehabilitation, a high level of uric acid in blood stream still maintained and joint destruction progressed. The only chance to improve the function of the locomotor system considering this patient it seems to be a surgical procedure removing the tophi around the joints or a new generation of drugs such as: febuxostat.
Downloads
References
Conway R. The real world of gout. The Journal of Rheumatology 2013; 6: 755-757
Gińdzieńska-Sieśkiewicz E., Sierakowski S,Domysłowska I , Sulik A. Dna moczanowa- aktualne spojrzenie na diagnostykę i leczenie. Reumatologia 2010; 6:425-428
Sivera F, Andrés M, Carmona L i wsp. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014; 73:328–335
Dalbeth N, Fransen J, Jansen TL, Neogi T, Schumacher HR, Taylor WJ. New classification criteria for gout: a framework for progress. Rheumatology 2013; 10:1748-1753.
Majdan M. Zapalenie stawów wywołane przez kryształy. W: Puszczewicz M : Wielka interna. Reumatologia, Warszawa, Medical Tribune Polska, 2010, 317-324
Roddy E, Doherty M. Treatment of hyperuricaemia and gout. Clin Med 2013; 13:400-403
Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009920.pub2/full (30.04.2013)
Goldfarb DS, Macdonald PA, Gunawardhana L, Chefo S, McLean L. Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones.Clin J Am Soc Nephrol. 2013; 11:1960-1967
Dalbeth N, House ME, Gamble GD i wsp.Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load.Ann Rheum Dis Ann Rheum Dis 2013; 11:1868-1873
Qing YF, Zhang QB, Zhou JG. Innate immunity functional gene polymorphisms and gout susceptibility. Gene 2013; 2:412–414
Meng DM, Zhou YJ, Wang L,i wsp. Polymorphisms in the NLRP3 gene and risk of primary gouty arthritis. Molecular Medicine Reports 2013; 6:1761-1766
Tran TH, Pham JT, Shafeeq H, Manigault KR, Arya V. Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy 2013; 7:744-753
Lee SS, Chen MC, Chou YH, Lin SD, Lai CS, Chen YC. Timing of intra-lesion shaving for surgical treatment of chronic tophus. Journal of Plastic, Reconstructive & Aesthetic Surgery 2013; 8:1131-1137
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw

This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.




